Crown Bioscience and NEXT Oncology Cement Partnership Extension
Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corporation, is pleased to announce the extension of its partnership with NEXT Oncology, one of the world’s largest Phase I Oncology Clinical Trial networks. This strategic partnership will continue to leverage Crown Bioscience's extensive experience in developing clinically relevant cancer organoid and patient-derived xenograft (PDX) models, together with NEXT Oncology's global clinical network and Phase I clinical trials expertise.
Through this extended agreement, Crown Bioscience reaffirms its exclusive rights to provide services based on patient samples sourced from NEXT Oncology’s industry-leading global clinical trial network. This collaboration underscores Crown Bioscience's commitment to providing the most clinically relevant PDX and organoid models and solutions for translational oncology research.
"We are thrilled to continue our exclusive partnership with NEXT Oncology," said John Gu, CEO of Crown Bioscience. "NEXT Oncology is globally recognized for its pioneering work in Phase I clinical oncology trials. Extending this partnership allows us to broaden our portfolio and strengthen our position as a leader in translational oncology platforms and integrated solutions. Our combined expertise and global reach will ensure rapid and scalable access to groundbreaking cancer models for our biopharma partners."
“NEXT Oncology is excited to continue our strong partnership with Crown Bioscience,” said Dr. Anthony Tolcher, CEO of NEXT Oncology. “Together, we will continue to develop new and highly relevant patient models that Crown’s biopharma partners can utilize to advance their translational oncology programs. Our combined efforts continue to support both companies’ missions to help cancer patients receive the most advanced medicines possible.”
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) dedicated to accelerating drug discovery and development in oncology and immuno-oncology. We partner with biotech and pharmaceutical companies to provide innovative, tailored solutions spanning preclinical research, translational platforms, and clinical trial support. With the world’s largest commercially available patient-derived xenograft (PDX) collection and approximately 1,000 tumor organoid models powered by Hubrecht Organoid Technology, we offer unparalleled insights across 35 cancer indications. Our expertise spans in vivo, in vitro, ex vivo, and in silico methods, complemented by advanced laboratory services that span the entire drug development continuum. Additionally, our extensive biobank of liquid and human biospecimens, complete with clinical histories, enhances oncology research capabilities. Operating from 11 state-of-the-art facilities across the US, Europe, and APAC, our laboratories meet the highest industry standards, including accreditation by the College of American Pathologists (CAP) and the International Organization for Standardization (ISO). To learn more, visit http://www.crownbio.com.
About NEXT Oncology
NEXT Oncology is dedicated to the development of new anticancer agents for patients whose current cancer therapy is no longer working to benefit them and are looking for their next option. NEXT Oncology is partnered with Texas Oncology, the largest private oncology practice in the United States with more than 400 referring medical oncologists. Texas Oncology is a practice within The US Oncology Network, a network of independent, community-based oncologists in the U.S. This formidable size and reach provide NEXT Oncology unprecedented opportunities to transform what has come to be expected from clinical trials of new agents.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250501393650/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EZVIZ Unveils HP7 Pro, Industry’s First 4K Palm Vein Video Doorphone, Making Home Entry Easier and Safer15.7.2025 10:30:00 CEST | Press release
EZVIZ pioneers next-level entry technology with the groundbreaking HP7 Pro 4K Palm Vein Video Doorphone. This innovative device redefines the internet-connected intercom by integrating secure unlocking with exceptional visual clarity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715927093/en/ The HP7 Pro marks an industry first, combining stunning 4K Ultra HD resolution with advanced palm vein scanning technology. This transforms it beyond communication – it becomes a secure smart lock and a vigilant smart camera, creating a personalized gateway for modern homes. Solving Real Access Challenges: "Traditional keys and passwords often fall short," says Binghong Wang, EZVIZ Product Research Lead. "The HP7 Pro’s AI-powered on-device recognition identifies who is at the door. Palm vein patterns are internal and nearly impossible to replicate, offering strong protection against spoofing. Simply wave your hand or glan
Payment Modernisation Is a Priority for 99% of EMEA Banks in the Next Year, Volante Report Reveals15.7.2025 10:00:00 CEST | Press release
New research from Volante Technologies reveals that replacing legacy systems is an urgent priority among EMEA banks, with institutions committing, on average, nearly $1.5 million to modernisation in the next year Volante Technologies, the global leader in Payments as a Service (PaaS), has released the fifth edition of its annual flagship research report, The Big Survey 2025: Modernising Payments. The survey of senior-level banking decision makers from 11 countries across EMEA reveals a near unanimous drive for change: 99% of banks plan to implement a new payments solution—replacing one or more systems—within the year, with over half (52%) aiming to do so in the next six months. Volante found that banks are not only keen to modernise, they are prepared to spend big to future-proof their payments infrastructure. Almost half (49%) of banks surveyed say their budget allocations for payments modernisation have increased over the past 12 months—on average, EMEA banks are planning to spend ju
Infobip Brings Voice Calling to WhatsApp Business Users15.7.2025 10:00:00 CEST | Press release
Enabling faster, trusted customer support with real-time voice calls inside WhatsApp Global cloud communications platform Infobip, today announced the launch of WhatsApp Business Calling, a new feature that enables businesses to make and receive voice calls via their WhatsApp Business numbers. This addition enhances Infobip’s omnichannel platform by delivering richer, real-time conversations within the messaging app used by millions worldwide. The feature allows businesses to receive and initiate voice calls globally, using WhatsApp’s native interface so customers never leave the app. Calls can be started directly from WhatsApp chats, interactive messages, or deep links embedded in websites and apps, providing multiple convenient entry points. Integration with Infobip Conversations, the company’s cloud contact center solution, enables customer support agents to switch seamlessly from chat to voice while maintaining unified conversation history and context. “Our customers tell us voice
PUMA and Manchester City Announce Long-Term Extension to Successful Global Partnership15.7.2025 09:45:00 CEST | Press release
Sports company PUMA and Premier League football club Manchester City have signed a long-term extension of their partnership, which since the 2019/20 season has exceeded all expectations on and off the pitch. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715122401/en/ Sports company PUMA and Premier League football club Manchester City have signed a long-term extension of their partnership, which since the 2019/20 season has exceeded all expectations on and off the pitch. The contract extension will allow PUMA and Manchester City to continue to innovate and create products that appeal to the club’s ever-growing global community of fans over the coming seasons. “PUMA’s partnership with Manchester City has been a great success both on and off the pitch,” said PUMA Chief Executive Officer Arthur Hoeld. “Trophies, a perfect stage for our performance products and commercial success were exceptional.” PUMA has celebrated many s
Autonomous Agents Set to Revolutionize Transportation Management15.7.2025 09:00:00 CEST | Press release
Global research from Manhattan Associates finds integration difficulties and data quality remain significant hurdles for organizations looking to leverage AI across transportation management Manhattan Associates Inc. (NASDAQ: MANH), the global leader in supply chain commerce, today announced the findings of its latest collaboration with international research firm Vanson Bourne. The global research surveyed 1,450 senior decision-makers* from organizations in manufacturing, retail, wholesale, consumer goods, grocery and food & beverage sectors, across North America, Latin America, Europe and Australia. “Transportation is the backbone of supply chains, essential to ensuring goods are delivered on time to meet customer expectations,” commented Bryant Smith, director, Transportation Management Systems (TMS) at Manhattan Associates. “Yet, managing transportation is becoming increasingly complex, pressured by demands on shorter fulfilment times, capacity and cost efficiencies, tighter sustai
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom